|
|
Bone-targeted Tx for pt without active bone disease? If so, duration?Bone-targeted Tx for pt without active bone disease? If so, duration?Do you generally recommend bone-targeted treatment for patients with MM who do not have active bone disease? If so, for how long do you generally continue therapy?
Morgan G et al. Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res 2013;19(21):6030-8. Abstract Morgan G et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomized controlled trial. Lancet 2010;376(9757):1989-99. Abstract Engelhardt M et al. European Myeloma Network. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 2014;99(2):232-42. Abstract Raje N et al. Bone marker directed dosing of zoledronic acid for the prevention of skeletal complications in patients with multiple myeloma: Primary analysis results of the Z-MARK study. Proc ASH 2011;Abstract 5122. Pozzi S, Raje N. The role of bisphosphonates in multiple myeloma: Mechanisms, side effects, and the future. Oncologist 2011;16(5):651-62. Abstract Terpos E et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 2013;31(18):2347-57. Abstract |